Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity is attractive because its portfolio blends resilient diagnostics franchises with a pre-clinical life sciences business that is now seeing demand recovery as biotech funding improves, supporting the company’s FY26 organic growth guide increase from 2–3% to 4–5%. The Life Science Solutions segment, roughly 50% of revenue, has potential for +40% incremental margins on antibodies and reagents, while Signals software and AI-enabled tools such as Xynthetica and BioDesign could lift higher-margin recurring revenue. Durable moats in EUROIMMUN autoimmune testing and newborn screening—plus 90%+ share in reproductive health and >100-country newborn screening reach—add visibility, even as pro forma operating margin is expected to ramp toward 28.4% in FY26.

Revvity is viewed negatively because its most important growth engines are not yet clearly accelerating enough to justify a stronger fundamental case: Immunodiagnostics has slowed to mid-single-digit/high-single-digit growth excluding China, while the ex-China autoimmune franchise still has not proven it can sustainably reach the 9–11% level embedded in management’s longer-run expectations. The company also faces structural and cyclical headwinds, including declining birth rates that cap Reproductive Health demand, tougher comparisons as the GEL contract annualizes in 2026, and continued sensitivity to biopharma and academic funding, currency, and country risk across North America, Europe, and Asia. Although the planned China Immunodiagnostics divestiture should remove a drag on growth and cash flow, the timing is uncertain and the broader life sciences recovery remains muted, leaving the downside scenario of roughly 17x earnings and a $105 valuation more plausible than a near-term reacceleration.